Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from Eµ-Myc B-cell lymphoma

ABSTRACT: We used microarrays to understand gene expression changes in response to DNA crosslinking agent mafosfamide over a 48 hour period. We also created resistant cell lines (R100, R500, R1000, R2000, R4000) via dose escalation and used microarrays to probe expression changes between the parental and resistant cell lines.

ORGANISM(S): Mus musculus

PROVIDER: GSE60342 | GEO | 2014/08/13

SECONDARY ACCESSION(S): PRJNA258063

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression data from EÂµ-Myc B-cell lymphoma

Project description:We used microarrays to understand gene expression changes in response to DNA crosslinking agent mafosfamide over a 48 hour period. We also created resistant cell lines (R100, R500, R1000, R2000, R4000) via dose escalation and used microarrays to probe expression changes between the parental and resistant cell lines. EÂµ-Myc B-cells were co-cultured in vitro with 750nM mafosfamide for 48 hours. Samples were collected at 0, 6, 12, 24, and 48 hours. Additionally, resistant lines were either treated or untreated with 750nM for 24 hours.

2014-08-13 | E-GEOD-60342 | biostudies-arrayexpress

Epigenetic Analysis of Eµ-Myc B-cell lymphoma using both H3K27me3 CHiP-Seq and Bisulfite-Seq (reduced representation).

Project description:We used RRBS and H3K27me3 to understand epigenetic changes in resistant cell lines to DNA crosslinking agent, mafosfamide, (Parental, R100, R500, R1000, R2000, R4000) via dose escalation.

2016-03-08 | GSE78939 | GEO

Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.

Project description: Not available

| S-EPMC5864240 | biostudies-literature

Transgenic Eµ-myc mouse lymphoma expression data for training dataset

Project description:We used gene expression data from Eµ-myc mouse lymphomas to perform unsupervised analyses that identified two lymphoma subgroups. We also used this data to develop a genomic signature to classify new lymphomas. When Eµ-myc mice had evidence of lymphoma and/or ill appearance, they were humanely sacrificed and dissected. Lymphoma tissue was obtained and flash frozen in liquid nitrogen. Later, lymphoma tissue was homogenized, and RNA was extracted. Gene expression microarrays were performed with the isolated RNA.

2014-09-10 | E-GEOD-40756 | biostudies-arrayexpress

Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.

Project description: Not available

| S-EPMC5029604 | biostudies-literature

Transgenic Eµ-myc mouse lymphoma expression data for test dataset [Mouse430_2]

Project description:We used gene expression data from Eµ-myc mouse lymphomas to test various genomic signatures and select lymphomas for further study When Eµ-myc mice had evidence of lymphoma and/or ill appearance, they were humanely sacrificed and dissected. Lymphoma tissue was obtained and flash frozen in liquid nitrogen. Lymphoma was dissociated into a single cell suspension, and cell pellets were frozen. Later, lymphoma tissue or cells were homogenized, and RNA was extracted. Gene expression microarrays were performed with the isolated RNA.

2014-09-10 | E-GEOD-40757 | biostudies-arrayexpress

Transgenic Eµ-myc mouse lymphoma expression data for test dataset [Mouse430A_2]

Project description:We used gene expression data from Eµ-myc mouse lymphomas to test various genomic signatures and select lymphomas for further study When Eµ-myc mice had evidence of lymphoma and/or ill appearance, they were humanely sacrificed and dissected. Lymphoma tissue was obtained and flash frozen in liquid nitrogen. Lymphoma and spleens were dissociated into single cell suspensions, and cell pellets were frozen. Later, lymphoma tissue or cells were homogenized, and RNA was extracted. Gene expression microarrays were performed with the isolated RNA.

2014-09-10 | E-GEOD-40758 | biostudies-arrayexpress

Transgenic Eµ-myc mouse lymphoma array CGH data

Project description:We used array CGH data from Eµ-myc lymphomas to assess significant differences in DNA copy number variation between Cluster 1 and Cluster 2 lymphomas.

2014-09-10 | GSE40759 | GEO

Transgenic Eµ-myc mouse lymphoma array CGH data

Project description:We used array CGH data from Eµ-myc lymphomas to assess significant differences in DNA copy number variation between Cluster 1 and Cluster 2 lymphomas. When Eµ-myc mice had evidence of lymphoma and/or ill appearance, they were humanely sacrificed and dissected. Lymphoma tissue was obtained and flash frozen in liquid nitrogen. Later, lymphoma tissue was homogenized, and genomic DNA was extracted. Array CGH was performed on genomic DNA, with genomic DNA from normal background strain mice used as the reference.

2014-09-10 | E-GEOD-40759 | biostudies-arrayexpress

Resistance to PRMT5-targeted therapy in mantle cell lymphoma

Project description:Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma, and patients who relapse on targeted therapies have poor prognosis. Protein arginine methyltransferase 5 (PRMT5), an enzyme essential for B-cell transformation, drives multiple oncogenic pathways and is overexpressed in MCL. Despite the antitumor activity of PRMT5 inhibition (PRT-382/PRT-808), drug resistance was observed in a patient-derived xenograft (PDX) MCL model. Decreased survival of mice engrafted with these PRMT5 inhibitor-resistant cells vs treatment-naive cells was observed (P = .005). MCL cell lines showed variable sensitivity to PRMT5 inhibition. Using PRT-382, cell lines were classified as sensitive (n = 4; 50% inhibitory concentration [IC50], 20-140 nM) or primary resistant (n = 4; 340-1650 nM). Prolonged culture of sensitive MCL lines with drug escalation produced PRMT5 inhibitor-resistant cell lines (n = 4; 200-500 nM). This resistant phenotype persisted after prolonged culture in the absence of drug and was observed with PRT-808. In the resistant PDX and cell line models, symmetric dimethylarginine reduction was achieved at the original PRMT5 inhibitor IC50, suggesting activation of alternative resistance pathways. Bulk RNA sequencing of resistant cell lines and PDX relative to sensitive or short-term-treated cells, respectively, highlighted shared upregulation of multiple pathways including mechanistic target of rapamycin kinase [mTOR] signaling (P < 10-5 and z score > 0.3 or < 0.3). Single-cell RNA sequencing analysis demonstrated a strong shift in global gene expression, with upregulation of mTOR signaling in resistant PDX MCL samples. Targeted blockade of mTORC1 with temsirolimus overcame the PRMT5 inhibitor-resistant phenotype, displayed therapeutic synergy in resistant MCL cell lines, and improved survival of a resistant PDX.

2024-04-09 | GSE229517 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data